AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21934054 — intervention group
Group type: COMPARATOR
Intervention: LRPR
Number of subjects: 1789
Study 21934446 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-seropositive women
Number of subjects: 3744
Study 21934446 — intervention group
Group type: COMPARATOR
Intervention: HIV-seronegative women
Number of subjects: 3744
Study 21935635 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68, a multiple tyrosine kinase inhibitor
Number of subjects: 25
Study 21935916 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-resistant cohort
Number of subjects: 74
Study 21935916 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-sensitive cohort
Number of subjects: 74
Study 21937232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 293
Study 21937232 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 293
Study 21937277 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on days 1 and 8 every 3 weeks)
Number of subjects: 128
Study 21937701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d on days 1-21 of a 28-day cycle
Number of subjects: 38
Study 21937701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 38
Study 21939529 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ initial
Number of subjects: 168
Study 21939529 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ occlusion slope
Number of subjects: 168
Study 21939529 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-derived StO₂ recovery slope
Number of subjects: 168
Study 21939939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 25
Study 21940776 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD-2-EP
Number of subjects: 138
Study 21940776 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD-4-EP
Number of subjects: 138
Study 21940776 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Constrictors
Number of subjects: 138
Study 21940776 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 138
Study 21940824 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated E coli asparaginase
Number of subjects: 329
Study 21940824 — intervention group
Group type: COMPARATOR
Intervention: native E coli asparaginase
Number of subjects: 329
Study 21940824 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia chrysanthemi asparaginase
Number of subjects: 329
Study 21940838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide (various doses based on body weight or absolute doses, administered either intravenously or subcutaneously, every 4 or 2 weeks)
Number of subjects: 139
Study 21940838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide (every 4 weeks)
Number of subjects: 139
Study 21940838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide (various doses)
Number of subjects: 139
Study 21941281 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting signalling pathways involved in PNI and pain generation.
Number of subjects: 0
Study 21941281 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 21941283 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improving outcomes in ovarian cancer
Number of subjects: 0
Study 21942531 — intervention group
Group type: EXPERIMENTAL
Intervention: SDP (SUMAVEL DosePro) administered for ≤4 migraine attacks over ≤60 days
Number of subjects: 90
Study 21942991 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention targeting nurses' attitudes and knowledge concerning cancer-related pain management.
Number of subjects: 0
Study 21942991 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of guidelines for systematic daily pain assessments following the educational intervention.
Number of subjects: 0
Study 21943381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 127
Study 21943381 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without psychiatric disorders
Number of subjects: 127
Study 21943381 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with resolved psychiatric disorders
Number of subjects: 127
Study 21943381 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persistent psychiatric disorders
Number of subjects: 127
Study 21944261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style, low-glycemic-load diet plus medical food (MF) containing phytosterols, soy protein, and extracts from hops and Acacia
Number of subjects: 83
Study 21944261 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-style, low-glycemic-load diet (control group)
Number of subjects: 83
Study 21945698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-B (Boostrix)
Number of subjects: 0
Study 21945698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-A (Adacel)
Number of subjects: 0
Study 21945953 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy discontinued
Number of subjects: 115
Study 21945953 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab re-treatment after relapse
Number of subjects: 115
Study 21947381 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFRcre (CKD-EPI)
Number of subjects: 448
Study 21947399 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 36
Study 21948234 — intervention group
Group type: EXPERIMENTAL
Intervention: T1/T2 cells (5 × 10(6) cells/kg)
Number of subjects: 9
Study 21948234 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (identically treated except for T1/T2 product infusions)
Number of subjects: 9
Study 21949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physicians' views on care levels
Number of subjects: 627
Study 21949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors leading to aggressive practice
Number of subjects: 627
Study 21949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives impact on diagnostic testing
Number of subjects: 627
Study 21949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in physician practices
Number of subjects: 627
Study 21949230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of IL-1beta
Number of subjects: 0
Study 21951550 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD and asthma
Number of subjects: 119
Study 21951550 — intervention group
Group type: COMPARATOR
Intervention: COPD alone
Number of subjects: 119
Study 21951596 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV antiretroviral therapy
Number of subjects: 0
Study 21951809 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 12
Study 21951809 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-constipation patients
Number of subjects: 12
Study 21951809 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 12
Study 21951987 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study 21953248 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days
Number of subjects: 27
Study 21953853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) therapy for patients with RVT for up to 2 years
Number of subjects: 409
Study 21953853 — intervention group
Group type: COMPARATOR
Intervention: No VKA therapy for patients without RVT
Number of subjects: 409
Study 21955300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest patients
Number of subjects: 100
Study 21955300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a proven genetic cause
Number of subjects: 100
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of saturated fat
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of trans fat
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of added sugar
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of vegetable and fruit fiber
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable and fruit fiber intake (in participants with family history of type 2 diabetes)
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake
Number of subjects: 205
Study 21955650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total fat intake
Number of subjects: 205
Study 21956038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 21956038 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between Bi-V pacing and preimplantation QRS width
Number of subjects: 0
Study 21956038 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-paced QRS width
Number of subjects: 0
Study 21956038 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-paced QRS width ≤ 200 ms
Number of subjects: 0
Study 21956423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Number of subjects: 31
Study 21956423 — intervention group
Group type: COMPARATOR
Intervention: Glucose-sweetened beverages
Number of subjects: 31
Study 21956955 — intervention group
Group type: COMPARATOR
Intervention: C-IFAZn
Number of subjects: 780
Study 21956955 — intervention group
Group type: COMPARATOR
Intervention: C-IFA
Number of subjects: 780
Study 21956955 — intervention group
Group type: EXPERIMENTAL
Intervention: M-IFAZn + C-IFA or C-IFAZn
Number of subjects: 780
Study 21958326 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) in the highest quartile (Q4)
Number of subjects: 982
Study 21958326 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) in TnT positive patients (TnT > 0.01 ng/mL) in the highest quartile (Q4)
Number of subjects: 982
Study 21958326 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hsCRP) in the highest quartile (Q4)
Number of subjects: 982
Study 21958326 — intervention group
Group type: COMPARATOR
Intervention: B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP)
Number of subjects: 982
Study 21958674 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based practices (EBPs)
Number of subjects: 176
Study 21958674 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration among systems leaders
Number of subjects: 176
Study 21958674 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networks of information and advice
Number of subjects: 176
Study 21958674 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice seeking and network structure
Number of subjects: 176
Study 21958674 — intervention group
Group type: COMPARATOR
Intervention: Counties that decided not to implement a specific EBP
Number of subjects: 176
Study 21959320 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA)
Number of subjects: 30
Study 21959320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 30
Study 21959320 — intervention group
Group type: EXPERIMENTAL
Intervention: ABSORB BVS
Number of subjects: 30
Study 21960318 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil)
Number of subjects: 154
Study 21963211 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21963957 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network-based approach to endoscopic ultrasound elastography
Number of subjects: 258
Study 21964801 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 10 mg/m²
Number of subjects: 14
Study 21964801 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 15 mg/m²
Number of subjects: 14
Study 21964801 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg/m²
Number of subjects: 14
Study 21964801 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (all doses)
Number of subjects: 14
Study 21965374 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX-brief (2 mcg/kg bolus over 10 minutes)
Number of subjects: 17
Study 21965374 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX-prolong (2 mcg/kg bolus plus 1 mcg/kg/hr infusion as needed)
Number of subjects: 17
Study 21965811 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-sign algorithm
Number of subjects: 7587
Study 21965811 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-sign algorithm
Number of subjects: 7587
Study 21965811 — intervention group
Group type: EXPERIMENTAL
Intervention: YIS7 algorithm
Number of subjects: 7587
Study 21966356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INFγ)
Number of subjects: 813
Study 21966356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma-induced protein 10 (IP10)
Number of subjects: 813
Study 21966356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 813
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in ex-smokers
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in never-smokers
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype involving SNP rs1898671
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in independent cohort study
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in ex-smokers in independent cohort study
Number of subjects: 599
Study 21966427 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in never-smokers in independent cohort study
Number of subjects: 599
Study 21967976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clofarabine 40 mg/m(2) per day, cyclophosphamide 440 mg/m(2) per day, etoposide 100 mg/m(2) per day for 5 consecutive days
Number of subjects: 25
Study 21967976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clofarabine, cyclophosphamide, and etoposide
Number of subjects: 25
Study 21968545 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg/5 ml bolus)
Number of subjects: 30
Study 21968545 — intervention group
Group type: COMPARATOR
Intervention: Adenosine (140 μg/kg/min)
Number of subjects: 30
Study 21969340 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 1.5 T with pacing mode changed to asynchronous for pacemaker-dependent patients and to demand for others
Number of subjects: 438
Study 21969340 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 1.5 T
Number of subjects: 438
Study 21969517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m² plus gemcitabine 1,000 mg/m²
Number of subjects: 67
Study 21969517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine
Number of subjects: 67
Study 21971123 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with incidental durotomy
Number of subjects: 389
Study 21971123 — intervention group
Group type: COMPARATOR
Intervention: Surgery without incidental durotomy
Number of subjects: 389
Study 21973271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 21974483 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified music exposure
Number of subjects: 0
Study 21974483 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard music exposure parameters
Number of subjects: 0
Study 21974763 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP Knowledge Test (HKT)
Number of subjects: 885
Study 21975150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Resurfacing Arthroplasty (HRA)
Number of subjects: 84
Study 21975150 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Replacement (THR)
Number of subjects: 84
Study 21975153 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective ventral hernia repair (study group)
Number of subjects: 2258
Study 21975153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no poor outcomes)
Number of subjects: 2258
Study 21975221 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [28, (17-39.5) μg/L] for those who died after 6 months follow-up.
Number of subjects: 9
Study 21975221 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [13.5, (10.5-32) μg/L] for those who survived after 6 months follow-up.
Number of subjects: 9
Study 21975221 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [20.5, (10.5-39.5) μg/L].
Number of subjects: 9
Study 21975322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver lasting less than 120 minutes (Group 1)
Number of subjects: 189
Study 21975322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver lasting more than 120 minutes (Group 2)
Number of subjects: 189
Study 21976132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m² every 21 days (phase 1)
Number of subjects: 46
Study 21976132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily and docetaxel 75 mg/m² every 21 days (phase 2)
Number of subjects: 46
Study 21976132 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent dasatinib after docetaxel discontinuation
Number of subjects: 46
Study 21976540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258) at 400 mg/d
Number of subjects: 47
Study 21976540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Number of subjects: 47
Study 21976672 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib 1200 mg
Number of subjects: 64
Study 21976672 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib 800 mg, 1200 mg, and 1600 mg
Number of subjects: 64
Study 21976672 — intervention group
Group type: EXPERIMENTAL
Intervention: Barasertib
Number of subjects: 64
Study 21976674 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning and transplantation of unrelated umbilical cord blood and CD34(+) stem cells from a haploidentical family member
Number of subjects: 45
Study 21977353 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (200 to 400 mg/d)
Number of subjects: 1395
Study 21977355 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician counseling that medication use was safe despite FDA warning
Number of subjects: 96
Study 21977355 — intervention group
Group type: COMPARATOR
Intervention: FDA warning reporting a 5% chance of birth defects with use
Number of subjects: 96
Study 21978972 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 543
Study 21978972 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI
Number of subjects: 543
Study 21978972 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR
Number of subjects: 543
Study 21978972 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for FLAIR imaging
Number of subjects: 543
Study 21978972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 543
Study 21981988 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 5298
Study 21981988 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (Control)
Number of subjects: 5298
Study 21982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Number of subjects: 3
Study 21982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacridar
Number of subjects: 3
Study 21982118 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 11-7082
Number of subjects: 3
Study 21982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 3
Study 21982118 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study 21982342 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 0
Study 21982342 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 0
Study 21982650 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes substudy in ≥1,500 patients
Number of subjects: 10000
Study 21982650 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world treatment including rate and rhythm control, stroke prevention, transitions to new therapies
Number of subjects: 10000
Study 21983216 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (2 doses for group 1, 1 dose for group 2)
Number of subjects: 284
Study 21983625 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer physical activity behavior change intervention
Number of subjects: 256
Study 21983625 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 21984541 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 30
Study 21984804 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-CAR T cells (CAR-ATCs and CAR-CTLs)
Number of subjects: 19
Study 21985945 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole tumor or lymph node (Whole)
Number of subjects: 0
Study 21985945 — intervention group
Group type: EXPERIMENTAL
Intervention: SliceMax
Number of subjects: 0
Study 21985945 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial
Number of subjects: 0
Study 21985945 — intervention group
Group type: EXPERIMENTAL
Intervention: 95Max
Number of subjects: 0
Study 21986637 — intervention group
Group type: EXPERIMENTAL
Intervention: BM MSCs derived from patients with critical leg ischemia
Number of subjects: 0
Study 21986637 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0